Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

ABT - Abbott Laboratories Latest News | Finranks

Home

ABT

A

Abbott Laboratories (ABT)

NYQ – Real Time Price. Currency in USD

103.99

-0.58 (-0.55%)

At close: Mar 27, 2026, 4:01 PM EDT

103.88

-0.11 (-0.11%)

After-hours: Mar 27, 2026, 7:56 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Abbott hosts conference call for first-quarter earnings

Abbott hosts conference call for first-quarter earnings

ABBOTT PARK, Ill., March 26, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2026 financial results on Thursday, April 16, before the market opens.

John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening

John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening

Potentially awkward conversations and 90s nostalgia combine to drive accessible screening for adults 45+ Learn more at Cologuard.com/TheTalk ABBOTT PARK, Ill., March 24, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a new campaign encouraging people to stop avoiding awkward conversations about colorectal cancer.

Abbott completes acquisition of Exact Sciences

Abbott completes acquisition of Exact Sciences

Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segments Advances Abbott's mission to make healthcare more accessible and give people more control over their health ABBOTT PARK, Ill., March 23, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has completed the acquisition of Exact Sciences, establishing Abbott as a leader in fast-growing cancer screening and diagnostics segments and enabling the company to serve millions of additional people.

2 Defensive Healthcare Stocks to Buy Right Now

2 Defensive Healthcare Stocks to Buy Right Now

Defensive stocks should help your portfolio weather the toughest market times. The revenue growth of these companies doesn't depend on the economic backdrop.

Best Dividend Aristocrats As Of March 20, 2026

Best Dividend Aristocrats As Of March 20, 2026

Dividend Aristocrats, tracked via NOBL, outperformed SPY YTD despite a sharp March pullback, with 44 Aristocrats beating SPY and 17 posting double-digit gains. Momentum, valuation (via dividend yield theory), and projected long-term total return now guide Aristocrat selection, with 39 currently screening as undervalued and offering ≥10% expected annualized returns. Recent dividend increases from CL, GD, LIN, and O bring the 2026 average Aristocrat dividend growth rate to 3.40%, with Realty Income expected to announce further hikes throughout the year.

Abbott acquisition of Exact Sciences set to close on March 23, 2026

Abbott acquisition of Exact Sciences set to close on March 23, 2026

Announcement follows receipt of all regulatory clearances necessary for closing Transaction enables Abbott to enter and lead in fast-growing cancer screening and diagnostics segments, serving millions of additional people ABBOTT PARK, Ill., March 20, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that it expects to close the acquisition of Exact Sciences on Monday, March 23, 2026.

1 Magnificent Dividend Stock Down 22% That's a Screaming Buy Right Now

1 Magnificent Dividend Stock Down 22% That's a Screaming Buy Right Now

Abbott Laboratories' latest financial results were not particularly strong. Some of the company's opportunities could help boost sales growth.

Videos

No Data

There is no data to display

Press releases

John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening

John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening

Potentially awkward conversations and 90s nostalgia combine to drive accessible screening for adults 45+ Learn more at Cologuard.com/TheTalk ABBOTT PARK, Ill., March 24, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a new campaign encouraging people to stop avoiding awkward conversations about colorectal cancer.

Abbott completes acquisition of Exact Sciences

Abbott completes acquisition of Exact Sciences

Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segments Advances Abbott's mission to make healthcare more accessible and give people more control over their health ABBOTT PARK, Ill., March 23, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has completed the acquisition of Exact Sciences, establishing Abbott as a leader in fast-growing cancer screening and diagnostics segments and enabling the company to serve millions of additional people.

Abbott acquisition of Exact Sciences set to close on March 23, 2026

Abbott acquisition of Exact Sciences set to close on March 23, 2026

Announcement follows receipt of all regulatory clearances necessary for closing Transaction enables Abbott to enter and lead in fast-growing cancer screening and diagnostics segments, serving millions of additional people ABBOTT PARK, Ill., March 20, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that it expects to close the acquisition of Exact Sciences on Monday, March 23, 2026.

Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management

Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management

U.K. FreeDM2 randomized controlled trial: At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks 1,2 Improvements were participant-led, using real-time glucose readings to guide everyday decisions Complementary Italian study reported similar improvements, reinforcing the value of Libre technology for this population3 ABBOTT PARK, Ill.